Utilization of Methionine Sources for Growth and Met plus Cys Deposition in Broilers

Simple Summary Methionine (Met) is the first limiting amino acid in broiler feeds and for balancing dietary Met and methionine+cysteine (Met+Cys) levels. DL-2-hydroxy-4-methylthio butanoic acid (HMTBA) and DL-methionine (DLM) are typical feed additives. The relative bioavailability value (RBV) describes the nutritional value of HMTBA relative to DLM and is important for adequate, precise, and cost-effective broiler nutrition. The current broiler feeding trial revealed an average RBV of 63% compared to DLM and the inclusion of an internal standard into the experimental design allowed for validation of the methodological approach. Evaluation of the utilization of supplemental Met sources for Met+Cys deposition in body protein provided further evidence for a higher efficiency and, thus, nutritional value of DLM over HMTBA. Knowledge about the nutritional value of methionine sources is highly important for their appropriate application in terms of animal and economic performance. Therefore, a broiler feeding trial was conducted to determine the relative bioavailability value (RBV) of DL-2-hydroxy-4-methylthio butanoic acid (HMTBA) compared to DL-methionine (DLM). DLM diluted to 65% purity (DLM65) served as the internal standard, with a known RBV of 65%. A total of 1920 d-old male broilers were used in the three-phase feeding trial comprising 16 treatments including a basal, Met+Cys-deficient diet and 5 graded DLM, HMTBA, or DLM65 levels. Growth performance and carcass quality data were subjected to multi-exponential regression analysis. Increasing levels of any Met source significantly improved all performance parameters compared to the negative control (p < 0.05). Across all performance parameters, the RBV of HMTBA was 63% and that of DLM65 was 58%. All RBV estimates of HMTBA and DLM65 were significantly lower than 88% (p < 0.05). Cumulative efficiency of DLM for Met+Cys deposition in body protein was higher than that of HMBTA at any dose, confirming the determined RBV. Using DLM65 as an internal marker allowed for validation of the methodology.